---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-025274"
form_type: "8-K"
ticker: "PTIX"
cik: "0001022899"
company_name: "Protagenic Therapeutics, Inc.new"
filed_at: "2025-08-22T23:59:59+00:00"
generated_at: "2026-05-17T10:28:57.120984+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Protagenic: Nasdaq non-compliance for late 10-Q; auditor changed; PT00114 Phase I dosing complete

## Summary
- Dismissed MaloneBailey as auditor, engaged Green Growth CPAs as new independent auditor effective August 7, 2025.
- Received Nasdaq deficiency notice on Aug 20, 2025 due to late filing of Q2 2025 Form 10-Q; trading continues under PTIX.
- Expects to file overdue 10-Q soon; will submit compliance plan within 60 days if needed.
- Completed first dose injection for all subjects in multiple-dose portion of Phase I trial of PT00114; topline safety data expected by end of September.

## SEC filing metadata
- accession: 0001641172-25-025274
- form_type: 8-K
- ticker: PTIX
- cik: 0001022899
- company_name: Protagenic Therapeutics, Inc.new
- filed_at: 2025-08-22T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01, 4.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022899/000164117225025274/0001641172-25-025274-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022899/000164117225025274/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-025274
- JSON: https://secwatch.observer/filing/0001641172-25-025274.json
- Plain text: https://secwatch.observer/filing/0001641172-25-025274.txt

## Key facts
- Auditor Changes
  Protagenic Therapeutics, Inc.new dismissed MaloneBailey, LLP as its auditor.
  - Action: dismissal
  - Auditor: MaloneBailey, LLP
  - Successor: Green Growth CPAs
  source text: On August 7, 2025, MaloneBailey, LLP (“MaloneBailey”) was dismissed as the independent registered public accounting firm of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1022899/000164117225025274/0001641172-25-025274-index.htm
- Listing & Compliance Notices
  Protagenic Therapeutics, Inc.new received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: late filing
  - Rules: 5250(c)(1)
  source text: August 20, 2025, the Company received a notice (the “Notification Letter”) from the Nasdaq Listing Qualifications department (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of the Form 10-Q. The notice does not immediately effect the listing or trading of the Company’s securities, which continue to trade on the Nasdaq Capital Market under the symbol “PTIX.” The Company intends to submit a plan to regain compliance within 60 calendar days of the Notification Letter, and Nasdaq may grant an exception of up to 180 calendar day
  evidence_url: https://www.sec.gov/Archives/edgar/data/1022899/000164117225025274/0001641172-25-025274-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.